Stocktoria
ELUTIA INC. ELUT
ELUTIA INC. (ELUT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $12.3M at a 434.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.492 |
| Retained earnings / assets | -2.826 |
| EBIT / assets | -0.432 |
| Equity / liabilities | 0.798 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
| ACOG | Alpha Cognition Inc. | 2/9 | 3.69 | — | — |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| TSHA | Taysha Gene Therapies, Inc. | 4/9 | -0.53 | — | — |
| CRIS | CURIS INC | 2/9 | — | — | -13.4% |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
About ELUTIA INC.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
FAQ
Is ELUT financially healthy?
ELUTIA INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ELUT pay a dividend?
No, ELUTIA INC. does not currently pay a dividend.
How profitable is ELUT?
In FY2025, ELUTIA INC. had a net margin of 434.2% and a return on equity of 192.9%.
What is ELUT's P/E ratio?
ELUTIA INC.'s trailing price-to-earnings (P/E) ratio is about 0.8×, based on its latest annual earnings.
What is the analyst price target for ELUT?
The average Wall-Street price target for ELUTIA INC. is $5.00, about 511.2% above the recent price, from 1 analysts.
Is ELUT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ELUTIA INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 0.8×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.